Susquehanna International Group, LLP Bio Line Rx Ltd. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 18,032 shares of BLRX stock, worth $3,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,032

Previous 118,180 84.74%

Holding current value

$3,967

Previous $67,000 86.57%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.53 - $0.87 $53,078 - $87,128	-100,148 Reduced 84.74%	18,032 $9,000
Q2 2024 Aug 15, 2024	SELL	$0.56 - $0.86 $48,571 - $74,591	-86,734 Reduced 42.33%	118,180 $67,000
Q1 2024 May 07, 2024	BUY	$1.03 - $1.56 $77,167 - $116,875	74,920 Added 57.63%	204,914 $229,000
Q4 2023 Feb 14, 2024	SELL	$1.31 - $1.86 $140,618 - $199,656	-107,342 Reduced 45.23%	129,994 $204,000
Q3 2023 Nov 14, 2023	BUY	$1.23 - $2.45 $188,482 - $375,433	153,238 Added 182.21%	237,336 $431,000
Q2 2023 Aug 11, 2023	BUY	$0.96 - $1.78 $80,734 - $149,694	84,098 New	84,098 $134,000
Q2 2022 Aug 15, 2022	SELL	$1.06 - $1.82 $37,110 - $63,718	-35,010 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.46 - $2.18 $51,457 - $76,834	-35,245 Reduced 50.17%	35,010 $60,000
Q4 2021 Feb 14, 2022	SELL	$1.98 - $3.06 $14,701 - $22,720	-7,425 Reduced 9.56%	70,255 $143,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $3.35 $205,852 - $260,228	77,680 New	77,680 $212,000

Others Institutions Holding BLRX

# of Institutions

Shares Held

3.35M

Call Options Held

46.5K

Put Options Held

6.3K

View Full List

About BioLineRx Ltd.

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $13.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

More about BLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Bio Line Rx Ltd. Transaction History